Get the Stockscreener App
1.605
2.23%
0.035
Skye Bioscience Inc stock is traded at $1.605, with a volume of 11,195.
It is up +2.23% in the last 24 hours and down -23.93% over the past month.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
See More
Previous Close:
$1.57
Open:
$1.6
24h Volume:
11,195
Relative Volume:
0.37
Market Cap:
$7.11M
Revenue:
Net Income/Loss:
$-57.33M
P/E Ratio:
-1.1106
EPS:
-1.4452
Net Cash Flow:
$-42.44M
1W Performance:
-4.46%
1M Performance:
-23.93%
6M Performance:
-74.05%
1Y Performance:
-86.89%
1-Day Range:
$1.55
$1.65
1-Week Range:
$1.50
$1.77
52-Week Range:
$1.50
$13.28
Skye Bioscience Inc Stock (SKYE) Company Profile
Name
Skye Bioscience Inc
Sector
Industry
Phone
(858) 410-0266
Address
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc
|
1.605 | 7.11M | 0 | -57.33M | -42.44M | -1.4452 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-06-25 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-15-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Sep-30-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-09-24 | Initiated | Craig Hallum | Buy |
| May-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-24 | Initiated | Oppenheimer | Outperform |
View All
Skye Bioscience Inc Stock (SKYE) Latest News
What's Driving the Buzz Around Skye Bioscience, Inc. (SKYE) in Cannabis Stocks? - Kalkine Media
Skye Bioscience director Andrew Schwab sells $239,555 in common stock - Investing.com
Form 4 Skye Bioscience Inc For: 25 September By Investing.com - Investing.com Canada
Form 4 Skye Bioscience Inc For: 25 September By Investing.com - Investing.com India
Form 4 Skye Bioscience Inc For: 25 September By Investing.com - Investing.com UK
Two 5AM funds sold Skye Bioscience (SKYE) shares; one day's weighted average price was $1.61. - Stock Titan
A 25.7% stake and share sales feature in Skye Bioscience (SKYE)'s ownership update. - Stock Titan
Two 5AM entities sold Skye Bioscience (SKYE) shares at $1.65 and a weighted average $1.61. - Stock Titan
How Did Skye Bioscience (NASDAQ:SKYE) Regain Nasdaq Compliance? - Kalkine Media
5am Partners VII, LLC sells $64,733 in Skye Bioscience stock By Investing.com - Investing.com Canada
Skye Bioscience director Andrew Schwab sells $64,733 in shares - Investing.com
5am Partners VII, LLC sells $64,733 in Skye Bioscience stock - Investing.com
Skye Bioscience (NASDAQ: SKYE) insider sells 33,892 shares at $1.91 - Stock Titan
5AM funds sell Skye Bioscience (SKYE) shares after reverse split - Stock Titan
Skye Bioscience, Inc. Common Stock (NASDAQ: SKYE) Share Price, SKYE Stock News, SKYE Share Price & Updates - kalkine.ca
Skye Bioscience CFO Resigns, CEO Punit Dhillon Takes Over Financial Reporting - minichart.com.sg
Skye Bioscience CFO Resigns, CEO Assumes Financial Role - TipRanks
Skye Bioscience Says John Sharp Resigns As CFOSEC Filing - TradingView
Skye Bioscience Ends Master Services Agreement With Lohman & Associates After CFO Resignation - TradingView
$SKYE BIOSCIENCE INC (SKYE.US)$ - Moomoo
$SKYE BIOSCIENCE INC (SKYE.US)$ Now we getting somewhere! [Cheerlead] - Moomoo
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Skye Bioscience Inc (SKYE) Stock Price, Quote, News & History - Benzinga
SKYE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Skye Bioscience (SKYE) Shares Rise 6% After Hours: Here's What's Driving The Move - Benzinga
Total debt per share of Skye Bioscience, Inc. – FWB:09R0 - TradingView
Price to book forward of Skye Bioscience, Inc. – FWB:09R0 - TradingView
Operating margin % of Skye Bioscience, Inc. – FWB:09R0 - TradingView
Skye Bioscience, Inc. Income Statement – FWB:09R0 - TradingView
Skye Bioscience (SKYE) Shares Rise 6% After Hours: Here's What's Driving The Move - webull.com
Skye BioscienceEnters $22 Million Securities Purchase Agreement With Redmile Biopharma Investments IiiSEC Filing - TradingView
Skye Bioscience Secures Up to $22 Million ELOC and Issues $5 Million Warrant to Redmile - TradingView
Skye Bioscience (NASDAQ: SKYE): Why Is A reverse share split taking effect in the current trading window in Focus Now? - Kalkine Media
Stock splits calendar for: - Yahoo Finance Singapore
Skye Bioscience director Andrew Schwab sells $140,313 in stock By Investing.com - Investing.com India
Skye Bioscience director Andrew Schwab sells $140,313 in stock By Investing.com - Investing.com UK
Skye Bioscience director Andrew Schwab sells $140,313 in stock - Investing.com
5am Partners VII, LLC sells $140,313 of Skye Bioscience stock - Investing.com
Skye Bioscience (SKYE) insider funds sell 375,840 shares at $0.32–$0.41 - Stock Titan
Skye Bioscience (SKYE) 5AM funds sell at penny-level prices - Stock Titan
Skye Bioscience director Andrew Schwab sells $140,313 in stock - Investing.com
5am Partners VII, LLC sells $140,313 of Skye Bioscience stock - Investing.com
5AM Partners VII disposes of 375,840 Skye Bioscience shares worth $134,482.80 - Bitget
Skye Bioscience, Inc. Common Stock (NASDAQ: SKYE) Share Price, SKYE Stock News, SKYE Share Price & Updates - Kalkine
Form 8K Skye Bioscience Inc For: 19 August By Investing.com - Investing.com South Africa
Skye Bioscience flags Nasdaq noncompliance after stockholders’ equity falls to ($497,307) - Bitget
SKYE BIOSCIENCE INC(SKYE) Stock Options Chain | Quotes & News - Moomoo
Form 8K Skye Bioscience Inc For: 19 August By Investing.com - Investing.com Nigeria
Skye Bioscience Faces Nasdaq Compliance and Delisting Risk - TipRanks
Form 8K Skye Bioscience Inc For: 19 August By Investing.com - Investing.com India
Skye Bioscience Inc Stock (SKYE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Skye Bioscience Inc Stock (SKYE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| 5AM Partners VII, LLC | 10% Owner |
Sep 23 '26 |
Sale |
1.61 |
119,379 |
192,200 |
0 |
| Schwab Andrew J. | Director |
Sep 22 '26 |
Sale |
1.65 |
28,700 |
47,355 |
4,528 |
| 5AM Partners VII, LLC | 10% Owner |
Sep 22 '26 |
Sale |
1.65 |
28,700 |
47,355 |
4,528 |
| 5AM Partners VII, LLC | 10% Owner |
Sep 16 '26 |
Sale |
1.91 |
33,892 |
64,734 |
5,616 |
| Schwab Andrew J. | Director |
Sep 16 '26 |
Sale |
1.91 |
33,892 |
64,734 |
5,616 |
| Schwab Andrew J. | Director |
Aug 20 '26 |
Sale |
0.32 |
7,700 |
2,464 |
55,208 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 20 '26 |
Sale |
0.32 |
7,700 |
2,464 |
55,208 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 19 '26 |
Sale |
0.35 |
68,140 |
23,849 |
55,254 |
| Schwab Andrew J. | Director |
Aug 19 '26 |
Sale |
0.35 |
68,140 |
23,849 |
55,254 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 18 '26 |
Sale |
0.38 |
300,000 |
114,000 |
55,663 |
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):